Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease.
Gómez-Sámano Miguel ÁngelVargas-Abonce Valerie PaolaMartínez-Sánchez Froylan DavidPalacios-Báez LucíaVera-Zertuche Juan MauricioNavarro-Flores María FernandaMorales-García Mariana GuadalupeFonseca-Correa Jorge IgnacioZuarth-Vázquez Julia MaríaVega-Vega OlynkaCorrea-Rotter RicardoRincón-Pedrero RodolfoMorales-Buenrostro Luis EAlberú-Gómez JosefinaRamírez-González Julia BerenicePacheco-Domínguez Reyna LizetteLópez-Cervantes MalaquíasMendoza-de-la-Garza María de Los ÁngelesBaeza-Arias Yolanda VictoriaEspinosa-Cuevas ÁngelesLópez-Carrasco GuadalupeLópez-Estrada AngelinaGuillén-Pineda Luz ElizabethGómez-Pérez Francisco JCuevas-Ramos DanielPublished in: Therapeutic advances in endocrinology and metabolism (2021)
A positive association between serum FGF21 and OS has been found independently of renal function in humans. Results from the present study provide novel information for deeper understanding of the role of FGF21 in OS in humans with CKD and T2D; mechanistic studies to explain the association of serum FGF21 with oxidative stress in CKD are needed.